ARTICLE | Clinical News
Intravenous 31510: Phase I started
December 16, 2013 8:00 AM UTC
Berg LLC, Boston, Mass. Product: Intravenous 31510 ( BPM 31510) Business: Cancer Molecular target: NA Description: Formulation of ubidecarenone, an endogenous small molecule resident in mitochondria ...